-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652A.O1.6 652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes Clinically Relevant Abstract

Symposia: Multiple Myeloma: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, genomics, Diseases, Lymphoid Malignancies, Biological Processes, molecular biology
Monday, December 11, 2023: 2:45 PM-4:15 PM
Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
Moderators:
Annamaria Brioli, MD, PhD, Universitätsmedizin Greifswald and Adam S. Sperling, MD, PhD, Brigham and Women's Hospital
Disclosures:
Brioli: Janssen: Honoraria, Other: Partecipation to Advisory Board; Travel Support; BMS: Honoraria, Other: Partecipation to Advisory Board; Travel Support; Sanofi: Honoraria, Other: Partecipation to Advisory Board; Travel Support; StemLine Menarini: Other: Partecipation to Advisory Board; Amgen: Honoraria, Other: Travel Support; AstraZeneca: Honoraria, Other: Travel Support; GSK: Honoraria, Other: Partecipation to advisory board. Sperling: Novartis: Consultancy; Roche: Consultancy.
The abstracts in this session utilize molecular and serum biomarkers to predict outcomes in patients with smoldering multiple myeloma and newly diagnosed multiple myeloma
2:45 PM
877
Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Theresia Akhlaghi1, David Nemirovsky, MS2*, Kylee H Maclachlan, MBChB, PhD3, Neha Korde, MD3, Sham Mailankody, MBBS3, Alexander Lesokhin, MD3, Hani Hassoun, MD3, Dhwani Patel, MD3*, Urvi A Shah, MD4, Carlyn Tan, MD3, Oscar Boutros Lahoud5, Heather Landau, MD5, Gunjan L. Shah5, Michael Scordo6, David Chung, MD, PhD6, Ola Landgren, MD7, Sergio A. Giralt, MD, FACP8, Saad Z Usmani, MD9, Andriy Derkach, PhD2* and Malin Hultcrantz, MD, PhD3

1Hematology and Medical Oncology, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, NY
2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
3Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Myeloma Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
5Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
6Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
8Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY
9Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3:00 PM
878
Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple MyelomaClinically Relevant Abstract

Daniel Wong1*, John Reynold2*, Cameron Wellard, BSc (Hons), PhD3*, Nicholas Bingham, BSc, MBBS, FRACP, FRCPA4*, Jessie Zhao5*, Malarmathy Ramachandran6*, Hang Quach, MD, FRACP, FRCPA, MBBS7, Simon Gibbs, FRACP, FRCPA, MBBS8*, Tiffany T. Khong, BSc, PhD9*, Sridurga Mithraprabhu, PhD, MSc2* and Andrew Spencer, MBBS, MD, FRACP, FRCPA10,11,12*

1Department of Haematology, Alfred Health, Melbourne, Australia
2Alfred Health, Melbourne, Australia
3School of Public Health and Preventative Medicine, Monash University, Melbourne, AUS
4alfred health, melbourne, Australia
5TH, Melbourne, Vic, Australia
6Monash University, Melbourne, VIC, AUS
7St. Vincent's Hospital Melbourne, East Melbourne, Australia
8Eastern Health, Box Hill, Australia
9ALFRED HOSPITAL, Melbourne, VIC, AUS
10Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia
11Department of Malignant Haematology & Stem Cell Transplantation, The Alfred Hospital, Melbourne, Australia
12Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
3:15 PM
879
The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple MyelomaClinically Relevant Abstract

Wenqiang Yan1*, Chen Qiu2*, Chenxing Du, MD3*, Shuhui Deng4*, Weiwei Sui5*, Yan Xu, MD5*, Dehui Zou6*, Weiping Yuan, MD, PhD7, Lugui Qiu5 and Gang An2*

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, TIANJIN, CHN
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, China
3Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin City, CHN
4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, CHN
5State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & PUMC, Tianjin, China
3:30 PM
880
Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma PatientsClinically Relevant Abstract

Ioannis V Kostopoulos, Msc. PhD1*, Ioannis Ntanasis-Stathopoulos, MD, PhD2*, Pantelis Rousakis, Msc.1*, Evangelos Eleutherakis-Papaiakovou, MD2*, Chrysanthi Panteli1*, Panagiotis Malandrakis, MD2*, Nikolaos Angelis1*, Nikolaos Kanellias, MD, PhD2*, Georgia Dimitrakopoulou1*, Foteini Theodorakakou, MD2*, Despina Fotiou, MD, PhD2*, Magdalini Migkou, MD, PhD2*, Maria Gavriatopoulou, MD, PhD2*, Efstathios Kastritis, MD2*, Meletios A. Dimopoulos3, Ourania Tsitsilonis, MD, PhD1* and Evangelos Terpos, MD, PhD4

1Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Drosia, Attiki, Greece
3:45 PM
881
Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation – Results from the Optimum/Muknine TrialClinically Relevant Abstract

Martin F. Kaiser, MD, FRCP, FRCPath1,2, Rachel Phillip3*, Andrew Hall3*, Amy Holroyd4*, Laura Bevington4*, Ruth M de Tute, MSc, PhD, FRCPath5*, Laura Clayton3*, Sadie Roberts3*, Graham Jackson6*, Gordon Cook, PhD7,8*, Richard S Houlston4*, Mark Drayson9*, Roger Owen, MD, MRCP, FRCPath10*, Guy Pratt11*, Sarah R Brown, PhD3* and Matthew W. Jenner12*

1The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
2The Institute of Cancer Research, London, ENG, United Kingdom
3Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
4The Institute of Cancer Research, London, United Kingdom
5HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
6Newcastle University, Newcastle, United Kingdom
7Leeds Cancer Centre, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
8Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom
9University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
10Leeds Teaching Hospitals NHS Trust, Haematological Malignancies Diagnostics Service, Leeds, United Kingdom
11University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
12University Hospital Southampton, Southampton, United Kingdom
4:00 PM
882
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple MyelomaClinically Relevant Abstract

Carolina Schinke, MD1, Leo Rasche, MD2*, Cody Ashby, PhD1*, Rudy van Hemert, MD3*, Sharmilan Thanendrarajan, MD1*, Samer Al Hadidi, MD, MSc1, Maurizio Zangari, MD1, Clyde Bailey, BS4*, Daisy V. Alapat, MD5, John D Shaughnessy, Jr, PhD1*, Fenghuang Zhan, MD, PhD1, Bart Barlogie, MD, PhD6*, Frits van Rhee, MD, PhD1 and Niels Weinhold, PhD7*

1Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
2Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
3Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR
4Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for Medical Sciences, Little Rock, AR
5Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR
6Myeloma Center, Winthrop P. Rockefeller Cancer Insitute, University of Arkansas for Medical Sciences, Little Rock, AR
7Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH